<ul>
<li>雷蒙德·詹姆斯被聘為財務顧問</li>
<li>實施裁員</li>
</ul>
<p>紐約，2026 年 1 月 30 日（全球新聞稿）—— IO Biotech（納斯達克：IOBT），一家開發新型免疫調節、現成的治療性癌症疫苗的臨牀階段生物製藥公司，今天宣佈已聘請雷蒙德·詹姆斯公司作為獨家財務顧問，協助公司進行之前宣佈的戰略選擇探索。</p>
<p>公司還宣佈正在實施成本控制和現金節約措施，包括大幅裁減公司員工，以降低運營費用，同時公司探索戰略選擇。</p>
<p><strong>關於 IO Biotech</strong></p>
<p>IO Biotech 是一家臨牀階段的生物製藥公司，基於其 T-win®平台開發新型免疫調節、現成的治療性癌症疫苗。T-win 平台基於一種新穎的癌症疫苗方法，旨在激活 T 細胞以靶向腫瘤細胞和腫瘤微環境中的免疫抑制細胞。IO Biotech 總部位於丹麥哥本哈根，並在美國紐約設有總部。有關更多信息，請訪問 www.iobiotech.com。請在 LinkedIn 和 X（@IOBiotech）上關注我們的社交媒體渠道。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條的修訂版的前瞻性聲明。前瞻性聲明，包括關於戰略選擇審查的性質、時間或結果，以及公司的財務狀況或現金流的聲明，基於 IO Biotech 當前的假設和對未來事件和趨勢的預期，這些事件和趨勢影響或可能影響其業務、戰略、運營或財務表現，實際結果和其他事件可能與這些聲明中表達或暗示的內容有重大不同，原因包括眾多風險和不確定性。前瞻性聲明本質上受到風險和不確定性的影響，其中一些無法預測或量化。由於前瞻性聲明本質上受到風險和不確定性的影響，您不應將這些前瞻性聲明視為未來事件的預測。這些前瞻性聲明僅在本聲明日期有效，不應被過度依賴。除法律要求的情況外，IO Biotech 不承擔更新這些聲明的義務，無論是由於任何新信息、未來發展還是其他原因。</p>
<p><strong>公司聯繫方式：</strong></p>
<p>艾米·沙利文，首席財務官</p>
<p>IO Biotech, Inc.</p>
<p>508-479-3480</p>
<p>asu@iobiotech.com</p>
<p><strong>雷蒙德·詹姆斯聯繫方式：</strong></p>
<p>布萊恩·格里森，董事總經理</p>
<p>雷蒙德·詹姆斯</p>
<p>(201) 988-5082</p>
<p>brian.gleason@raymondjames.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5qRXlNeU0zTkRBeE5UQTRJekl5TmpFME9ERT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5qRXlNeU0zTkRBeE5UQTRJekl5TmpFME9ERT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTM0ZDg3N2QtYmY3ZC00Yzk1LWExODctZDUwN2NiNjNiM2U3LTEyNzMwMzEtMjAyNi0wMS0zMC1lbg==/tiny/IO-Biotech.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTM0ZDg3N2QtYmY3ZC00Yzk1LWExODctZDUwN2NiNjNiM2U3LTEyNzMwMzEtMjAyNi0wMS0zMC1lbg==/tiny/IO-Biotech.png"/></p>

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

IOBT

醫藥突破 ETF - ALPS

IBBQ

動態生物技術與基因組 ETF - Invesco

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

IOBTQ

<p>IO Biotech（納斯達克代碼：IOBT）已聘請 Raymond James 作為其獨家財務顧問，以探索戰略選擇。該公司正在實施成本控制措施，包括大幅裁員，以降低運營費用。IO Biotech 專注於基於其 T-win®平台開發免疫調節癌症疫苗。公司總部位於丹麥哥本哈根，在美國紐約設有辦公室。關於公司財務狀況和戰略審查的前瞻性聲明面臨風險和不確定性</p>

<ul>
<li>Raymond James engaged as financial advisor</li>
<li>Reduction in force implemented</li>
</ul>
<div class="lb-trans"><ul>
<li>雷蒙德·詹姆斯被聘為財務顧問</li>
<li>實施裁員</li>
</ul>
</div><p>NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p>
<div class="lb-trans"><p>紐約，2026 年 1 月 30 日（全球新聞稿）—— IO Biotech（納斯達克：IOBT），一家開發新型免疫調節、現成的治療性癌症疫苗的臨牀階段生物製藥公司，今天宣佈已聘請雷蒙德·詹姆斯公司作為獨家財務顧問，協助公司進行之前宣佈的戰略選擇探索。</p>
</div><p>The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the company explores strategic alternatives.</p>
<div class="lb-trans"><p>公司還宣佈正在實施成本控制和現金節約措施，包括大幅裁減公司員工，以降低運營費用，同時公司探索戰略選擇。</p>
</div><p><strong>About IO Biotech</strong></p>
<div class="lb-trans"><p><strong>關於 IO Biotech</strong></p>
</div><p>IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).</p>
<div class="lb-trans"><p>IO Biotech 是一家臨牀階段的生物製藥公司，基於其 T-win®平台開發新型免疫調節、現成的治療性癌症疫苗。T-win 平台基於一種新穎的癌症疫苗方法，旨在激活 T 細胞以靶向腫瘤細胞和腫瘤微環境中的免疫抑制細胞。IO Biotech 總部位於丹麥哥本哈根，並在美國紐約設有總部。有關更多信息，請訪問 www.iobiotech.com。請在 LinkedIn 和 X（@IOBiotech）上關注我們的社交媒體渠道。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the nature, timing or outcome of a review of strategic alternatives, and the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1933 年證券法第 27A 條及 1934 年證券交易法第 21E 條的修訂版的前瞻性聲明。前瞻性聲明，包括關於戰略選擇審查的性質、時間或結果，以及公司的財務狀況或現金流的聲明，基於 IO Biotech 當前的假設和對未來事件和趨勢的預期，這些事件和趨勢影響或可能影響其業務、戰略、運營或財務表現，實際結果和其他事件可能與這些聲明中表達或暗示的內容有重大不同，原因包括眾多風險和不確定性。前瞻性聲明本質上受到風險和不確定性的影響，其中一些無法預測或量化。由於前瞻性聲明本質上受到風險和不確定性的影響，您不應將這些前瞻性聲明視為未來事件的預測。這些前瞻性聲明僅在本聲明日期有效，不應被過度依賴。除法律要求的情況外，IO Biotech 不承擔更新這些聲明的義務，無論是由於任何新信息、未來發展還是其他原因。</p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司聯繫方式：</strong></p>
</div><p>Amy Sullivan, CFO</p>
<div class="lb-trans"><p>艾米·沙利文，首席財務官</p>
</div><p>IO Biotech, Inc.</p>
<div class="lb-trans"><p>IO Biotech, Inc.</p>
</div><p>508-479-3480</p>
<div class="lb-trans"><p>508-479-3480</p>
</div><p>asu@iobiotech.com</p>
<div class="lb-trans"><p>asu@iobiotech.com</p>
</div><p><strong>Raymond James Contact:</strong></p>
<div class="lb-trans"><p><strong>雷蒙德·詹姆斯聯繫方式：</strong></p>
</div><p>Brian Gleason, Managing Director</p>
<div class="lb-trans"><p>布萊恩·格里森，董事總經理</p>
</div><p>Raymond James</p>
<div class="lb-trans"><p>雷蒙德·詹姆斯</p>
</div><p>(201) 988-5082</p>
<div class="lb-trans"><p>(201) 988-5082</p>
</div><p>brian.gleason@raymondjames.com</p>
<div class="lb-trans"><p>brian.gleason@raymondjames.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZME5qRXlNeU0zTkRBeE5UQTRJekl5TmpFME9ERT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY0NjEyMyM3NDAxNTA4IzIyNjE0ODE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OTM0ZDg3N2QtYmY3ZC00Yzk1LWExODctZDUwN2NiNjNiM2U3LTEyNzMwMzEtMjAyNi0wMS0zMC1lbg==/tiny/IO-Biotech.png" alt="" original-src="https://ml.globenewswire.com/media/OTM0ZDg3N2QtYmY3ZC00Yzk1LWExODctZDUwN2NiNjNiM2U3LTEyNzMwMzEtMjAyNi0wMS0zMC1lbg==/tiny/IO-Biotech.png"/></p>

IO Biotech 發佈公司最新動態 | IOBT 股票新聞